Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Operational Highlights
RMD logo

ResMed Drives 11% Revenue Growth to $1.423B on Device Sales Surge

RMD10-QFiling Date: 1/30/2026
ResMed Inc.
Description

What this story covers

ResMed's Q2 2026 10-Q shows 11% revenue growth to $1.423B, led by Sleep and Breathing Health segment, with gross margins at 61.8%. Operating income up 14% to $530M, cash flow surges 26%. Strategy emphasizes digital integration and acquisitions like VirtuOx amid low debt and hedging risks.

Story snapshot

CompanyResMed Inc.
TickerRMD
VariantStandard detailed
Duration13:59
Filing type10-Q
PeriodQ2 2026
IndustryHealthcare & Pharmaceuticals
Accession0000943819-26-000007

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in